Market Cap 124.36M
Revenue (ttm) 7.14M
Net Income (ttm) -2.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.39%
Debt to Equity Ratio 0.00
Volume 1,313,900
Avg Vol 5,375,340
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 82%
Beta 1.84
Analysts Strong Sell
Price Target $17.00

Latest News on CRVO

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 3 months ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed to Participate in Upcoming Investor Conferences

Nov 7, 2024, 8:30 AM EST - 4 months ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 8 months ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 11 months ago

CervoMed to Appoint William Elder as Chief Financial Officer


CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67


CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 66


CervoMed Announces Completion of Merger with EIP Pharma

Aug 16, 2023, 1:58 PM EDT - 1 year ago

CervoMed Announces Completion of Merger with EIP Pharma